Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14490967 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2POLBALDH1A1BCHEACHE | |
| SCHEMBL24709214 | 0.84 | HTR4 (0.40) | SMN1; SMN2ALDH1A1BCHEACHEITGB3 | |
| SCHEMBL7060631 | 0.84 | GSK3B (0.39) | SMN1; SMN2ALDH1A1BCHEACHELTA4H | |
| SCHEMBL7062612 | 0.83 | CYP1A2 (0.46) | SMN1; SMN2TSHRALDH1A1BCHEACHE | |
| SCHEMBL29098476 | 0.83 | HTR4 (0.39) | SMN1; SMN2POLBALDH1A1HTT | |
| SCHEMBL8608071 | 0.83 | HSD17B10 (0.44) | BCHEACHEITGB3ITGA2BF2R | |
| SCHEMBL11981721 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL28949811 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1LTA4H | |
| SCHEMBL7061429 | 0.79 | NAAA (0.40) | SMN1; SMN2ALDH1A1ITGB3ITGA2BF2R | |
| SCHEMBL7060557 | 0.78 | HTT (0.49) | SMN1; SMN2POLBALDH1A1BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | RICHTER GEDEON NYRT. (HU) | 2008-12-11 | — | — | US | disclosed |
| WO-2007072087-A2 | NOVEL PROCESS FOR PRODUCTION OF HIGHLY PURE POLYMORPH (I) DONEPEZIL HYDROCHLORIDE | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
| EP-1102746-B1 | SUBSTITUTED PHENYLAMIDINES WITH ANTITHROMBOTIC ACTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-05-14 | — | — | EP | disclosed |
| US-6242466-B1 | ANTICOAGULANTS, ANTITUMOR, ANTIMETASTASIS, ANTICARCINOGENIC, AND ANTIINFLAMMATORY AGENTS; BONE DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-06-05 | — | — | US | disclosed |
| EP-1102746-A1 | SUBSTITUTED PHENYLAMIDINES WITH ANTITHROMBOTIC ACTION | BOEHRINGER INGELHEIM KG (DE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000005207-A1 | SUBSTITUTED PHENYLAMIDINES WITH ANTITHROMBOTIC ACTION | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | DRD4, IDO1, ADH1A | SMN1; SMN2 3344/4885TSHR 3241/4885POLB 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.